PPBT VS AIH Stock Comparison

Performance

PPBT
10/100

PPBT returned -52.51% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

AIH
10/100

AIH returned -60.35% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

Technicals

PPBT
11/100

PPBT receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

AIH
11/100

AIH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

PPBT
10/100

PPBT has missed earnings 7 times in the last 20 quarters.

AIH
10/100

AIH has missed earnings 4 times in the last 20 quarters.

Profit

PPBT
11/100

Out of the last 20 quarters, PPBT has had 1 profitable quarters and has increased their profits year over year on 0 of them.

AIH
22/100

Out of the last 20 quarters, AIH has had 6 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

PPBT
48/100

PPBT has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

AIH
59/100

AIH has had a higher than average amount of volatility over the last 12 months giving it a score of 59 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Purple Biotech Ltd. American Depositary Shares Summary

Nasdaq / PPBT

Healthcare

Biotechnology

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Aesthetic Medical International Holdings Group Ltd. American Depositary Shares Summary

Nasdaq / AIH

Healthcare

Medical - Care Facilities

Aesthetic Medical International Holdings Group Limited provides aesthetic medical services. It offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments comprising minimally invasive and energy-based treatments, including laser, ultrasound, and ultraviolet light treatments. The company also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. It operates 15 treatment centers in China, Hong Kong, and Singapore. Aesthetic Medical International Holdings Group Limited was founded in 1997 and is headquartered in Shenzhen, the People's Republic of China.

Power up your portfolio